Condition

Stage IIIB Lung Non-Small Cell Cancer AJCC v7

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 19 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials19

Recruiting2

Common interventions25

Lead sponsors shown5

Clinical trials

19 shown

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 TherapyNCT04892953 · 2021-07-07

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeNCT03191149 · 2018-04-25

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung CancerNCT02503722 · 2017-03-23

ACTIVE_NOT_RECRUITING

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsNCT02498613 · 2016-08-31

ACTIVE_NOT_RECRUITING

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung CancerNCT02520778 · 2016-08-30

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung CancerNCT02321501 · 2016-06-22

ACTIVE_NOT_RECRUITING

FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT ImagingNCT02773238 · 2016-05-20

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ MalignanciesNCT02706392 · 2016-03-16

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung CancerNCT02535325 · 2015-09-30

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation TherapyNCT02452463 · 2015-06-29

Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryNCT01912625 · 2013-10-28

Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung CancerNCT01629498 · 2012-09-17

ACTIVE_NOT_RECRUITING

Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung CancerNCT01507428 · 2012-02-22

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryNCT01386385 · 2011-06-20

ACTIVE_NOT_RECRUITING

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung CancerNCT01413750 · 2010-11-08

Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination ChemotherapyNCT00693992 · 2008-06-15

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryNCT00334815 · 2006-06-15

ACTIVE_NOT_RECRUITING

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following SurgeryNCT00254384 · 2005-10-05

Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung CancerNCT00126581 · 2005-08-15

Common interventions

Leading sponsors

National Cancer Institute (NCI)12 M.D. Anderson Cancer Center4 Fred Hutchinson Cancer Center1 Roswell Park Cancer Institute1 University of Washington1

Trial status mix

COMPLETED7

ACTIVE_NOT_RECRUITING6

TERMINATED4

RECRUITING2

Phase mix

PHASE211

PHASE19

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.